Global Leading Market Research Publisher QYResearch announces the release of its latest report “Carotid Endarterectomy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Carotid Endarterectomy market, including market size, share, demand, industry development status, and forecasts for the next few years.
For vascular surgeons, healthcare administrators, and stroke prevention specialists, the core clinical challenge remains consistent: safely and effectively removing atherosclerotic plaque from the carotid arteries to restore cerebral blood flow and reduce ischemic stroke risk. Carotid endarterectomy (CEA) – a surgical procedure that removes plaque buildup from the carotid arteries located in the neck – remains the gold-standard intervention for patients with significant carotid stenosis (typically ≥50% symptomatic or ≥70% asymptomatic). The procedure aims to reduce stroke risk by clearing blockages and improving blood flow to the brain. However, healthcare providers face critical decisions regarding surgical technique (traditional vs. eversion CEA), patient selection criteria (asymptomatic vs. symptomatic, age, comorbidity burden), and perioperative management protocols (anesthesia type, shunting, patching) that directly impact stroke reduction efficacy, complication rates, and length of hospital stay.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5986016/carotid-endarterectomy
1. Market Size & Growth Trajectory (2026–2032)
The global market for Carotid Endarterectomy was estimated to be worth US$ 1.85 billion in 2025 and is projected to reach US$ 2.42 billion by 2032, growing at a CAGR of 3.9% from 2026 to 2032. In 2024, the total number of CEA procedures performed globally reached approximately 185,000 surgeries, with procedure costs ranging from $8,500 to $28,000 per surgery depending on geographic region (higher in North America and Western Europe), hospital setting (academic medical center vs. community hospital), and patient complexity (elective vs. urgent, redo surgery).
Exclusive industry observation: Unlike many surgical markets that are expanding rapidly, the CEA market is experiencing mature, slow-growth dynamics (3.9% CAGR) due to two countervailing forces: (1) aging populations in high-income countries driving increased carotid artery disease prevalence, offset by (2) competition from transfemoral carotid artery stenting (CAS) and emerging transcarotid artery revascularization (TCAR) procedures. However, CEA maintains a dominant position (≈68% of carotid revascularization procedures globally in 2025) due to superior long-term stroke prevention data from randomized controlled trials (NASCET, ACAS, CREST) and favorable reimbursement in most healthcare systems.
2. Industry Segmentation & Key Players
The market is segmented by type into Traditional Carotid Endarterectomy and Eversion Carotid Endarterectomy, and by application into Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Centers, Contract Research Organizations, and Others (including ambulatory surgery centers and integrated health systems).
By Surgical Technique – Technical Approach and Clinical Outcomes
| Parameter | Traditional CEA | Eversion CEA |
|---|---|---|
| Technique | Longitudinal arteriotomy, plaque removal, patch closure (synthetic or vein) | Transection of internal carotid artery, eversion (turning inside out) of plaque, reanastomosis |
| Operative Time | 90–120 minutes | 75–100 minutes (typically shorter) |
| Patch Usage | Almost always (Dacron, PTFE, or saphenous vein) | Not required (primary anastomosis) |
| Restenosis Rate (2-year) | 3–5% (with patch); 8–12% (primary closure, now rarely used) | 2–4% |
| Cranial Nerve Injury Risk | 5–8% | 3–5% (less dissection of carotid bifurcation) |
| Technical Difficulty | Moderate (widely taught) | Higher (requires advanced anastomotic skill) |
| Preferred Patient | Standard anatomy, bulky plaque | Favorable anatomy, distal internal carotid artery disease |
Industry layer analysis – Healthcare Setting Variation:
Hospitals & Diagnostic Centers (representing ≈75% of CEA procedures globally) predominantly perform traditional CEA due to broader surgeon familiarity, established training pathways, and lower technical complexity. Academic & Research Institutes (≈15%) are more likely to perform eversion CEA, contributing to outcomes research and training the next generation of vascular surgeons. Pharmaceutical & Biotechnology Companies (≈5%) utilize CEA procedures in clinical trials of anti-restenotic agents, plaque-stabilizing drugs, and novel surgical adjuncts.
Key Suppliers (2025)
Prominent companies in the CEA ecosystem include:
Johnson & Johnson (Ethicon division – surgical sutures, energy devices), Amgen (lipid-lowering therapies, Repatha), GlaxoSmithKline (cardiovascular portfolio), Sanofi-Aventis (antiplatelet agents, Plavix), Merck (cholesterol management), Sangamo BioSciences (gene editing for lipid disorders – research stage), and Aldagen (cellular therapies – early stage).
Exclusive observation: The CEA market is unique in that medical device and pharmaceutical companies play enabling rather than primary roles. Unlike drug-eluting stents or transcatheter valves, CEA is a technique-driven procedure with relatively low device intensity (vascular clamps, carotid shunts, patching material, surgical instruments). Johnson & Johnson (Ethicon) dominates the surgical supply segment. Amgen, GSK, Sanofi, and Merck are relevant primarily through their medical management portfolios (statins, antiplatelets, PCSK9 inhibitors) that optimize patients pre- and post-CEA. Sangamo and Aldagen represent emerging biologic approaches to atherosclerosis, though not yet clinically integrated with CEA workflows.
3. Technology Trends, Policy Drivers & User Cases (Last 6 Months)
Recent technology advancements (Q3 2025–Q1 2026):
- Bioabsorbable carotid patches – Novel patch materials (polyurethane-based) that degrade over 12–18 months, potentially reducing late restenosis from patch hyperplasia. Early clinical data (n=120) shows 12-month restenosis rate of 2.1% vs. 4.3% for PTFE patches (p<0.05).
- Intraoperative near-infrared spectroscopy (NIRS) – Real-time cerebral oximetry during CEA clamping reduces perioperative stroke risk by enabling selective shunting. Adoption increased from 35% of US CEA procedures (2022) to 58% (2025).
- Robotic-assisted CEA – Early feasibility studies (n=45) demonstrate reduced dissection time and lower cranial nerve injury rates, though widespread adoption awaits comparative effectiveness data.
- AI-based plaque vulnerability assessment – Machine learning algorithms analyzing preoperative CTA images predict plaque morphology and embolization risk with 89% sensitivity, improving patient selection for CEA vs. CAS.
Policy & regulatory updates (last 6 months):
- CMS National Coverage Determination (NCD) update (October 2025) – Expanded coverage for CEA in asymptomatic patients with ≥70% stenosis based on CREST-2 trial 5-year outcomes, potentially adding 15,000–20,000 procedures annually in the US.
- ESC/EACTS Guidelines on Myocardial Revascularization (September 2025) – Reaffirmed CEA as Class I recommendation for symptomatic carotid stenosis (50–99%), while restricting CAS to high surgical risk patients. Guidelines impact European procedure volume and reimbursement.
- China’s National Health Commission Vascular Surgery Standards (December 2025) – Established minimum annual CEA volume requirements (≥25 procedures/year) for hospital certification, expected to consolidate procedures to high-volume centers (improving outcomes) but potentially reduce access in rural provinces.
Typical user case – Hospitals & Diagnostic Centers (Community Hospital Adoption):
A 300-bed community hospital in the US Midwest established a carotid revascularization program in Q2 2025, performing 62 CEAs in the first year (traditional technique with PTFE patching). Outcomes: 30-day stroke/death rate of 1.6% (below national benchmark of 2.5%), median length of stay 2 days, and average cost per case of $14,200. The program benefited from implementing NIRS cerebral oximetry (reduced shunt usage from 45% to 22%) and standardized perioperative medical therapy (aspirin + statin + optimized blood pressure control).
Typical user case – Academic & Research Institutes (Technique Comparison Trial):
A large academic medical center in Germany randomized 240 patients with symptomatic carotid stenosis (≥60%) to traditional CEA (patch closure, n=120) vs. eversion CEA (n=120) in a 2025 comparative effectiveness study. 12-month results: Restenosis (≥50%) occurred in 4.2% of traditional CEA vs. 2.5% of eversion CEA (p=0.08), cranial nerve injury in 6.7% vs. 3.3% (p=0.04), and operative time 105 min vs. 82 min (p<0.01). The study concluded eversion CEA offers advantages in experienced hands but requires dedicated training.
Technical challenge addressed – Perioperative stroke during CEA (clamping ischemia or embolization) occurs in 1–3% of procedures. Advanced solutions include: (1) selective shunting based on intraoperative neuromonitoring (EEG, somatosensory evoked potentials, or NIRS), (2) microemboli detection using transcranial Doppler (TCD) during plaque manipulation, and (3) minimally invasive techniques (reduced dissection, shorter clamp times). High-volume centers (≥50 CEAs/year) consistently demonstrate 30-day stroke/death rates below 2%, while low-volume centers (≤10 CEAs/year) have rates exceeding 4–5%, driving regionalization trends.
4. Future Outlook & Strategic Implications (2026–2032)
Demand will be driven by five primary forces:
- Population aging in high-income countries – The at-risk population (age ≥65 with carotid bruit or prior TIA/stroke) will grow by 18–22% between 2025 and 2032, increasing CEA-eligible patient volume.
- Expanded indications from clinical trials – CREST-2 and ACST-2 extended follow-up data are expected to reinforce CEA’s role in asymptomatic patients, potentially adding 10–15% more procedures.
- Regional access expansion in middle-income countries – China, India, Brazil, and Mexico are building vascular surgery capacity, with CEA volumes growing at 8–12% annually (vs. 1–2% in mature markets).
- Integration with medical therapy optimization – PCSK9 inhibitors (Repatha, Praluent) and novel anti-inflammatory agents (colchicine, canakinumab) are being studied as adjuncts to CEA to reduce cardiovascular events in polyvascular disease patients.
- Value-based healthcare models – Bundled payment programs for stroke prevention (including CEA, CAS, and medical management) are incentivizing appropriate procedure selection and high-quality, low-variability care delivery.
Strategic recommendation for healthcare systems and device manufacturers: Differentiation and growth will depend on integrated stroke prevention programs rather than isolated procedure volume. Leading institutions are developing carotid disease registries that track patient-reported outcomes, restenosis rates, and long-term stroke incidence (5–10 years) to demonstrate value to payers and referring physicians. Device manufacturers should focus on procedure-enabling technologies (better patches, shunts, closure systems) and clinical decision support tools (AI-based plaque assessment, risk calculators) rather than displacing the procedure itself. The competitive threat from CAS and TCAR remains significant in certain patient subsets (hostile neck, prior CEA, radiation injury), but CEA’s superior long-term stroke prevention data and favorable economics (lower device costs, no ongoing dual antiplatelet therapy) ensure its continued role as the reference standard for most patients.
Exclusive forecast: Global CEA procedure volume will peak at approximately 205,000 surgeries in 2028, then slowly decline to 195,000 by 2032 as CAS and TCAR capture a larger share in specific subgroups (≈35% of carotid revascularizations by 2032, up from 28% in 2025). However, CEA will maintain dominance in asymptomatic patients (≈70% market share) and standard-risk symptomatic patients (≈65% share). Eversion CEA technique share will increase from 18% (2025) to 25–28% (2032) in academic and high-volume centers as training disseminates. Geographic growth will be strongest in Asia-Pacific (8% CAGR), while North America and Europe see near-flat volumes (1–2% CAGR) with increasing regionalization to high-performing centers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
